- 50+ Attendees from vaccine manufacturers, biotechs, NGOs, regulators & technology companies
- 15+ World class speakers from all around the world
- 20+ Hours of networking time
 - 3 Days of Intense Knowledge sharing





18 - 20 November 2014 Istanbul | Turkey

The FIRST and ONLY event focusing on MENA (Middle East and North Africa) as well as CIS (Commonwealth of Independent States) vaccine industry.

There will be a strong focus on partnerships, novel research and development as well as state of the art technical solutions.

DISTINGUISHED PANEL OF SPEAKERS

Dr. Ahmed Emara, CEO & Managing Director, ReAya Holding (Holding company of AraBio), Saudi Arabia



Dr. Stanley C. Erck, Chief Executive Officer, Novavax Inc, USA



Dr. Mutlu Topal, Managing Director, Keymen Ilac, Turkey



Prof. Dr. Bulent Gumusel, Dean of Pharmacy Faculty, Hacettepe University - Ankara, Turkey



Dr. Reinhard Glück, Chief Scientific Officer, Zydus Cadila, India



Dr. Kutub Mahmood, Scientific Director, Polio Vaccine Development Project, PATH, USA



Dr. Marc LaForce, Director - Technical Services, Serum Institute of India,



Prof. Sayadyan Khachik, CEO, NT Pharma, Russia



Prof. Dr. Mustafa Hacimustafaoğlu, Department of Pediatrics, Faculty of Medicine, Uludag University, Turkey



Dr. Bernd Eisele, Chief Executive Officer, Vakzine Projekt Management, Germany



Mr. K. V. Balasubramanium, Managing Director, Indian Immunologicals, India



Ms. Eman Aly, Vice President Middle East & North Africa, Sanofi Pasteur, Turkey



Dr. Daniel D.
Adams,
Executive Chairman
and Global Head
of Business
Development,
Protein Sciences
Corporation,
USA



Beril Tezcanli Quality Group Director, Mefar Ilac, Turkey



Syedah Maria Bokhari, Regional Vaccines Commercial Head -MENA & CIS, GSK, Turkey



Useful & organized conference. Really helpful.

Elizaveta Starodubova
Senior Researcher
Engelhardt Institute of Molecular Biology,
Russian Academy of Sciences, Russia
(Vaccine World CIS & CEE 2013)

Good conference, thanks to organizers.

K. Zaman

Head Vaccine Surveillance Research Group; Scientist and Epidemiologist, ICCDR, Bangladesh (Vaccine World India 2014)

Proudly created and produced by



2013 Sponsors & Exhibitors







Why you should attend Vaccine World MENA & CIS 2014?

- ✓ Learn about the latest trends in vaccine MENA and CIS industry
- ✓ Network with high level decision makers and KOLs in MENA and CIS
- ✓ Learn good manufacturing practices and manufacturing excellence to conform to international standards
- ✓ Discuss latest R&D and strategies for vaccine innovations
- ✓ Discuss how to accelerate vaccine R&D through interesting case studies and showcases

2014 Supporting Association



2014 Media Partners





Chairman's Letter

It's my sincere pleasure to welcome you to the inaugural of Vaccine World Summit MENA and CIS 2014, which will be held in Istanbul, Turkey from 18th – 20th November 2014. This event organized by IMAPAC will bring around 20 world class speakers to present and share their experiences and knowledge in Istanbul where two continents meet each other. Together, we will have a great opportunity to promote innovation and development for vaccines in MENA and CIS region so as to ensure adequate supply of high quality vaccines for our public.

Being a part of the vaccine industry gives each of us the ability to have a positive impact on the lives of millions of people that we will probably never meet. It is an honor and a pleasure to have the power to relieve the unnecessary suffering caused by infectious diseases and to perform a very significant service to the entire world.

While our work has already transformed many lives, we should not forget that over 9.5 million people die each year due to infectious diseases. Together we can improve this situation. This is why I encourage you to be part of the Vaccine World Summit, we welcome all public health professionals, NGOs, vaccine business leaders, academics and all other related stakeholders to be part of this global vaccine event.

This year we will focus on the latest success strategies for vaccines in MENA and CIS region, innovative partnership models, manufacturing technologies and novel research.

I am looking forward to seeing each and every one of you join us next November in Istanbul, Turkey. Let's share and listen together so we can share exciting new ideas, stimulate growth of the vaccine industry and improve lives of people worldwide.

Yours sincerely,

Dr. O. Mutlu Topal Managing Director, Keymen Ilac, Turkey; Vaccine World MENA and CIS Summit 2014



	IMAPAC'S Welcoming Remarks Chairman's Opening Remarks Key Note CEO Plenary Session: Gain Insights into the CIS and MENA current market	IMAPAC'S Welcoming Remarks Chairman's Opening Remarks New Vaccines, New Opportunities: Look into Nove
	Key Note CEO Plenary Session: Gain Insights into	, ,
		New Vaccines New Opportunities: Look into New
	landscape through Key Opinion Leaders in the Industry	Research & Development of Vaccines for the MEN. and CIS Region (ex: Kalar Azar Disease, Hepatitits (
	Speed Networking and Morning Refreshments	Morning Refreshments
	New Vaccines, New Opportunities: Look into Novel Research & Development of Vaccines for the MENA and CIS Region (ex: Collaborating with Academia, Polio and Influenza vaccines)	Vaccine Supply Chain Dialogue: Meeting Vaccine Demand for EPIs and UPIs, Working with Governme NGOs and NPO'S Forecasting and Managing supple and State of the art cold chain solutions
		Chairman's Closing Remarks
	Networking Lunch and Technical Seminars	Networking Lunch and Technical Seminars
IMAPAC'S Welcoming Remarks Chairman's Opening Remarks Making inroads into MENA and CIS Vaccine Market:	New Vaccines, New Opportunities: Look into Novel Research & Development of Vaccines for the MENA and CIS Region (ex: MERS and Meningococcal vaccines)	
Overview of Regulatory Framework in MENA and CIS Region and Market Access, Entry Strategies	Round Table Discussions: What factors to consider in developing a Robust and Innovation driven pipeline	
Afternoon Refreshments & Exhibition Visit	Afternoon Refreshments and Exhibition Visit	
Round Table Discussions: Looking into current partnership models, key	Vaccine Scale Up and Process Design Strategies: Optimizing cell culture, Cost - benefit analysis of Single use systems Fill & Finish	
considerations before entering the market	Round Table Discussions: Manufacturing economics and cost efficient processing	
Chairman's Closing Remarks	Chairman's Closing Remarks	

PRE-CONFERENCE DAY

18 NOVEMBER 2014

13:00 Registration commences

Overview of Regulatory Framework in MENA and CIS Region and Market Access, Entry Strategies

13:30

Making inroads into the MENA market: Current trends and partnership models in the MENA Vaccine market

- Successful partnership models and what make such partnerships work?
- Utilizing IP as a tool to develop, sustain and protect partnerships
- · Overcoming regulatory barriers via partnerships

Dr. Ahmed Emara, CEO & Managing Director, ReAya Holding, Saudi Arabia

13:55

Panel Discussion

Streamlining vaccine regulatory pathway to meet changing demand

- · Overcoming challenges in Implementing sustainable vaccine development programs in developing countries
- · Role of partnerships in policy strategizing and implementation.
- · Addressing the gaps in understanding of regulations

Mr. Cagdas Balci, Strategic Planning and Marketing Sales Operations Director, Novartis, Turkey

Invitation to: Prof. Dr. Secil Ozkan, Director of Public Health Directorate of Turkey Ankara, Turkey

Ms. Gihan Hamdy El-sisi, Team Leader of HPA, Central Administration for Pharmaceutical Affairs,

Ministry of Health and Population, Egypt

14:35

Afternoon Refreshments and Speed Networking

15:05

Testing commercial-ability of introducing vaccines into MENA and CIS market: MNC Perspective

- · Challenges and opportunities in the MENA and CIS market
- · Analysis of competitiveness and partnership opportunities for the CIS region

Ms. Syedah Maria Bokhari, Regional Vaccines Commercial Head - Middle East North Africa & CIS, GSK, Turkey

15:35

Establishing and managing long distance partnerships

- Analysis of competitiveness for the MENA and CIS region
- · Criteria that is looked into before entering a particular market
- Case studies

Dr. Bernd Eisele, Chief Executive Officer, Vakzine Projekt Management, Germany

Roundtable Discussions

16:00

Roundtable 1

Entering Emerging MENA and CIS Market

- Opportunities, Major challenges and how to avoid common pitfalls
- Commercial and operational considerations of successfully navigating the evolving regulatory framework

Roundtable 2

Balancing Cost Benefits of Venturing into New Market.

- Balancing Cost Benefits of Venturing into New Market.
- Best time and phase in vaccine development to start engaging distribution partners
- Criteria for choosing the right Distributors

16:50

Cocktail Reception



CONFERENCE DAY 1 19 NOVEMBER 2014

8:15	Registration Commences
8:55	IMAPAC's Welcome Remarks
9:00	Chairman's Opening Remarks

Key Note Panel Discussion

9:10 Keynote Roundtable

Gain Insights into the CIS and MENA current market landscape through Key Opinion Leaders in the Industry

- Overview of MENA and CIS Vaccine Market: Trends and opportunities
- Look into growth opportunities for this region
- How to position your company in the next 5 years and analyzing what need to be done to achieve continuous growth in MENA and CIS vaccine industry

Confirmed Panellists

Dr. O. Mutlu Topal, Managing Director, Keymen Ilac, Turkey

Dr. Ahmed Emara, CEO & Managing Director at ReAya Holding, Saudi Arabia

Invited Panellists.

Dr. Hechmi Louzir, Director General of Institut Pasteur de Tunis, Tunisia Professor Arkady Nekrasoy, CEO, NPO Petrovax Pharma, Russia

10:00 Morning Refreshments and Speed Networking

New Vaccines, New Opportunities: Focus on Vaccine Research and Development in MENA and CIS Region

10:45 Promoting R&D in the MENA region by collaborating with Academia

- Look into Novel Research & Development of Vaccines for the MENA and CIS Region

Prof. Dr. Bulent Gumusel, Dean of Pharmacy Faculty, Hacettepe University - Ankara, Turkey

11:10 Polio: Battling a versatile foe

- Advancement of IPV vaccine development
- Eradication of polio in the MENA region? What needs to be done in the coming years and role of regional vaccine manufactures and distributors

Dr. Kutub Mahmood, Scientific Director, Polio Vaccine Development Project, PATH, USA

11:35 Vaccines for the Future Session I – Focus on Influenza Vaccine

- Importance of Influenza Vaccination for the Middle East and CIS region
- Look into Novel Research & Development of Vaccines for the Influenza
- Case Study: AdeVac-Flu

Prof. Saiadian Khachik, CEO Abiolek Company & Director of Science, NTpharma, Russia

Lunch Networking Session 12:00

13:00 Vaccines for the Future Session I – Focus on MERS Vaccine

- Importance of MERS Vaccination for the Middle East region
- Look into Novel Research & Development of Vaccines for the MERS
- Case Study: nanoparticle vaccine for MERS-CoV by Novavax

Dr. Stanley C.Erck, Chief Executive Officer, Novavax Inc, USA

13:25 Vaccines for the Future Session II - Importance of Meningococcal Vaccines

Importance and of Meningococcal vaccination in the Middle Eastern region

Prof. Dr. Mustafa Hacımustafaoğlu, Department of Pediatrics, Faculty of Medicine, Uludag University, Turkey

Round Table Discussions

13:50

What factors to consider in developing a Robust and Innovation driven pipeline

- How to ensure that your research is economically viable in the vaccine industry
- Collaborative advantages of research and manufacturer partnerships
- Co-development partnerships and Technology Transfers: helping you to take your product to masses

Prayer Break and Afternoon Refreshment

Vaccine Scale Up and Process Design Strategies

14:45 **Evaluation of use of Single Use Technology**

- · Pros and cons of using disposable systems in upstream and downstream, small and large-scale processing
- Managing single use technology in clinical and commercial development; scaling up and down
 Testing and risk management of extractable and leachable in single use bioreactors

Reserved for Technology Solution Provider

15:10 The right attitude and equipment to ensure vaccine of the highest quality

- Implementing QBD in the vaccine development cycle
- Choosing the best suited technological systems for a low cost high volume production
- Case Study

Dr. Reinhard Glück, CSO, Zydus Cadila, India

15:35 **Optimizing Cell Culture**

- Methods and compositions for increasing longevity and protein yield from a cell culture
- How to improve process consistency Analysing transfer and scalability data for cell culture

Reserved for Technology Solution Provider

Vaccine manufacturing capabilities, challenges and opportunities in the MENA region

Mrs. Beril Tezcanli, Quality Group Director, Mefar Ilac, Turkey

Round Table Discussions

16:00

16:25 Manufacturing economics and cost efficient processing

- Designing downstream facilitates to align with upstream manufacturing strategies
- Cutting-edge automation, controls to increase downstream productivity Economic analysis of facility utilization, cost vs. product yield & purity

16:50 Chairman's Closing Remarks



CONFERENCE DAY 2 20 NOVEMBER 2014

8:30	Registration Commences	
9:00	Chairman's Opening Remarks	
Best Practises and Manufacturing Economics		
9:00	Trends & Challenges in Technical and Manufacturing Collaboration in MENA and CIS Region Identifying the right partner Evaluating platform technology, therapeutic focus & geographical focus Exploring manufacturing partnership structures: co-development, licensing opportunities & pitfalls to avoid Dr. Daniel D. Adams, Executive Chairman and Global Head of Business Development, Protein Sciences Corporation, USA	

9:25 State of the art engineering solutions and flexible facility planning

- Alternative approaches to ensure maximum productivity for multiple product manufacturing in a single space
- Automation technologies to improve productivity

Reserved for Technology solution provider

9:50 Fill and Finish Strategies - should we outsource?

- Outsourcing fill and finish functions advantages, disadvantages and cost benefit analysis
- Challenges faced during fill and finish process and how to overcome them

Dr. O.Mutlu Topal, Managing Director, Keymen Ilac, Turkey

Vaccine Supply Chain Dialogue

10:15 Morning Refreshments

Forecasting vaccine demand & supply in MENA and how does it affect vaccine manufacturers & distributors 10:45

- Price point pressures along the vaccine manufacturing process and how it impede growth of new vaccine development
- Role of NGOs: Pricing concerns in ensuring a sufficient vaccines supply
- Possible new initiatives or programs that can bridge supply gap

Ms. Eman Ali, Vice President, Business Unit Head, Turkey, Middle East and North Africa, Sanofi Pasteur, Turkey

11:10 Thermal stability of conjugate vaccines: the advantages of being able to take vaccines outside the cold chain

MenAfriVac case study

Dr. Marc LaForce, Director - Technical Services, Serum Institute of India, USA

11:35 State of the art Vaccine Cold Chain Management

- Challenges of cold chain management in the MENA region
- Meeting temperature sensitive requirements
- Utilizing novel technology and quality management systems to reduce spoilage


Reserved for Technology solution provider


12:00 Chairman's Closing Remarks


12:10 **Lunch Networking Sessions**

14:00 **End of Conference Proceedings**

ATTENDEE PROFILE FOR VACCINE WORLD MENA & CIS 2014







WHY SHOULD YOU SPONSOR?

Vaccine World MENA & CIS 2014 will provide commercial organizations with the opportunity to:

- Educate the market about what you offer
- ✓ Position yourselves as leaders in your field alongside key industry figures
- Raise brand awareness
- Enjoy the option of privately arranged meetings and consultations with selected potential clients
- ✓ Hold face-to-face meetings with your target profile

PLUS! Book early to take advantage of the world-class marketing campaign!

- ✓ 50+ touch points over 9 months
- ✓ 20,000+ individual communications
- Integrated campaign featuring web, social media, email, press releases etc
- ✓ Partnerships with leading international publications & associations

For more information on sponsorship & exhibition opportunities, contact:



Vibhas Pahuja
Business Development Manager
+65 6493 1598
vibhas.pahuja@imapac.com



SAMPLE LIST

Organizations that previously attended our Vaccine events

- Abiolek LLC
- Bill and Melinda Gates Foundation
- Czech Embassy
- Embassy of Ukraine to the Russian Federation
- Etna Biotech
- Kerry
- Microgen Holding
- Ministry of Health of Russian Federation
- MOH. Ukraine
- Nanolek
- NewVac
- Novartis Vaccines and Diagnostics, Inc.
- NPO Petrovax Pharm
- PALL International Sarl
- Pharmaceutical Industry Review
- Protein Sciences Corporation
- Russian Academy of Sciences
- Saint-Petersburg Institute of Vaccines & Sera of the Russian FMBA
- IBC Nanotex
- PALL Eurasia LLC
- Sanofi Pasteur
- Sartorius ICR / Biohit LLC
- Selecta Biosciences
- SOTIO
- US Commercial Service
- Vaxine
- VisMederi-SRL and many more

2013 Sponsors & Exhibitors:







REGISTRATION FORM

LIMITED SPECIAL **GENERAL PACKAGES &** EARLY BIRD **STANDARD OFFER DEADLINES PRICE** (By 1 Aug) 3 Day Conference Pass (18 - 20 November 2014) **GOVERNMENT/ACADEMIC** 795 USD 895 USD **VACCINE MANUFACTURERS** 1,195 USD 995 USD 1,395 USD 1,595 USD FROM BRIC (BRAZIL, RUSSIA & CIS, INDIA & CHINA) **GENERAL PRICING** 1,995 USD 2,195 USD 2,395 USD 2,595 USD

The registration fee includes refreshments, lunch and full conference documentation

The conference fee does not include hotel accomodation

YOUR DETAILS

Special discounts & eligibility (Only one discount scheme is applicable. Call Cecilia at +65 6493 2093 to obtain your discount codes):

- · ACADEMIC DISCOUNT International academics, NGOs, government and non-profit representatives enjoy up to 40% off the usual conference pricing
- INNER CIRCLE Speaker referrals & professionals working in the same organization as our speakers are entitled to a 15% discount.
- PRIZE FREEZE Clients of our sponsors & exhibitors can avail the first-tier price throughout the campaign, even after the deadline has passed!
- GROUP PACKAGES Save 10% for 3 delegates & 20% for 5 delegates
- PHARMACEUTICAL MANUFACTURERS ASSOCIATION OF TURKEY MEMBERS are entitled to a 20% discount off General Pricing.

Ivallic	
Job Title	Organizaton
Address	
Postcode	Country
Tel	Fax
Email	
Your primary business	
Authorising Manager	Authorising manager signature
By signing and returning this form, you are a	ccepting our terms and conditions.
PAYMENT DETAILS	
	his registration form if you pay by credit card or 3 working days after dit card payment will incur an additional US\$100
I want to pay Credit Card Nor	n-credit card and add US\$100 booking fee
Online credit card payment: Please register at: www.imapac.com/bus	siness_conference/vaccine-world-mena-and-cis-2014/pricing
Offline credit card payment: Visa MasterCard Amer	ican Express
Name on Card	Card Number
Expiry Date CVC Code	e Signature
For bank details & swift code, it will Cheque payment: Crossed cheque	nsfer must quote delegate name and conference name. be emailed to you as part of the invoice. payable to IMAPAC Pte Ltd, and mail it in a sealed envelope ad #16-09/13 Shaw Tower Singapore 189702



EVENT VENUE



18 - 20 November 2014 Istanbul | Turkey

4 Easy Ways to Register:

The quickest & easiest way to register is online using a credit card. Visit: www.imapac.com/ business conference/vaccineworld-mena-and-cis-2014/pricing

Telephone

To register over the phone, please call us on +65 6493 2093

By Fax

Please fax your booking form to +65 6722 0649

Mail

By cheque made payable to: **IMAPAC PTE. LTD.**

Send with this booking form to: IMAPAC PTE. LTD. 100 Beach Road #16-09/13 Shaw Tower Singapore 189702

Group Booking

Send your team & save more!

3 delegates SAVE 10% 5 delegates SAVE 20%

Call +65 6493 2093 or go online & register at: www.imapac.com/ business_conference/vaccineworld-mena-and-cis-2014/pricing

TERMS & CONDITIONS:

- Full payment is due upon registration if you pay by credit card, or 3 working days after receipt of invoice.
 Registration will not be confirmed until full payment has been received.
 Unpaid registration will be billed 50% of the registration fee if you do not attend the event. A copy of the conference documentation will be mailed to you.
 The registration fee includes refreshments, lunches, cooktails and full conference documentation. The conference fee does not include hotel accomodation.
 Staff at the event will request a credit card guarantee for delegates without proof of payment.

- CANCELLATION & SUBSTITUTION POLICY:

 Cancellations must be received in writing. If the cancellation is received more than 14 days before the conference attendees will receive a full credit note to a future conference. Cancellations received 14 days or less (including the fourteenth day) prior to the conference will be liable for the full fee.

 A substitution from the same organisation can be made at any time in writing at no extra charge.

 In the event that IMAPAC cancels a conference, payments received at the cancellation date will be credited towards attendance at a future conference or in the event of postponement by IMAPAC, towards the rescheduled date.

 Credit notes remain valid for twelve months.

CHANGES TO CONFERENCE & AGENDA: IMAPAC reserves the right to postpone or cancel an event, to change the location or alter the advertised speakers for an event. IMAPAC is not responsible for any loss or damage as a result of substitution, alteration, postponement or cancellation of an event due to causes beyond its control including without limitation, acts of God, natural disasters, sabotage, accident, trade or industrial disputes, terrorism or hostilities.

In the event that a conference is cancelled, IMAPAC is not liable for any costs incurred by delegates in connection with their attendance. Control to alter the content and timing of the programme, venue or the identity of the speakers without any liability to the delegates. Changes to the agenda will be updated on our website as soon as possible.

DATA PROTECTION: The personal information shown and/or provided by you will be held in a database. It may be used to keep you up to date with developments in your industry. Sometimes your details may be obtained or made available to reputable third parties for marketing purposes. If you do not wish your details to be used for this purpose, please write to: data@imapac.com.